1.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
2.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
3.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
4.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
5.Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.
Zhiyun CHENG ; Yinghui LV ; Suqiu PANG ; Ruyu BAI ; Mingxi WANG ; Shuyu LIN ; Tianwen XU ; Duncan SPALDING ; Nagy HABIB ; Ruian XU ;
Acta Pharmaceutica Sinica B 2015;5(3):194-200
Kallistatin, which protects organs and cells against inflammation, fibrosis and oxidative stress, is mainly synthesized and secreted in liver. However, its relationship to human liver disease remains unclear. The purpose of this study was to explore the relationship between serum kallistatin and clinical evidence of both cirrhosis and hepatocellular carcinoma (HCC), and to determine if serum kallistatin levels could be used as a diagnostic indicator of hepatic health status, especially human liver cirrhosis (LC). Our cohort consisted of 115 patients with clinically proven liver fibrosis (LF), LC, or HCC by liver biopsies, and 31 healthy controls (CON). Serum kallistatin levels were quantified by ELISA. Results of the present study demonstrated that irrespective of the underlying etiology, serum kallistatin levels were significantly lower in the LF/LC group when compared with the CON group. A decrease in serum kallistatin levels appeared to reflect the extent of cirrhosis, with the lowest levels associated with higher grades of cirrhosis. Patients with LC had a noticeable correlation between serum kallistatin levels and other serum biochemical indicators. The area under the curve (AUC) for LC, viral liver cirrhosis (VLC) and alcoholic liver cirrhosis (ALC) was 0.845, 0.757 and 0.931, respectively. In conclusion, our findings demonstrated that kallistatin, a plasma protein produced by the liver, can be a useful and reliable diagnostic indicator of hepatic health status, especially for LC.